Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

Jon Bjoern; Rikke Lyngaa; Rikke Andersen; Lisbet Hölmich Rosenkrantz; Sine Reker Hadrup; Marco Donia; Inge Marie Svane

doi:10.18632/oncotarget.26359

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

PDF | How to cite

Oncotarget. 2018; 9:35870-35870. https://doi.org/10.18632/oncotarget.26359

Metrics: PDF 1324 views | ?

Jon Bjoern^1,2, Rikke Lyngaa^3,1, Rikke Andersen^1,2, Lisbet Rosenkrantz Hölmich⁴, Sine Reker Hadrup^3,1, Marco Donia^1,2 and Inge Marie Svane^1,2

¹ Center for Cancer Immune Therapy, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
² Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
³ Section for Immunology and Vaccinology, Technical University of Denmark, Copenhagen, Denmark
⁴ Department of Plastic Surgery, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

Published: November 09, 2018

This article has been corrected: The correct name of the 4th author is as follows:

Lisbet Rosenkrantz Hölmich

Original article: Oncotarget. 2017; 8:27062-27074. DOI: https://doi.org/10.18632/oncotarget.16003.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26359

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma